Chicago Partners Investment Group LLC Purchases Shares of 1,877 Charles River Laboratories International, Inc. $CRL

Key Points

• Chicago Partners Investment Group LLC has purchased 1,877 shares of Charles River Laboratories International, Inc. for approximately $315,000, reflecting growing interest from institutional investors in the company.
• Analysts have recently upgraded their ratings and price targets for Charles River Laboratories, with Citigroup increasing its target from $150 to $200, and Jefferies raising the target from $142 to $195.
• Charles River Laboratories reported a positive quarterly earnings result of $3.12 EPS, surpassing the consensus estimate of $2.50, with a revenue of $1.03 billion, marking a 0.6% year-over-year increase.

Chicago Partners Investment Group LLC purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,877 shares of the medical research company's stock, valued at approximately $315,000.

A number of other institutional investors have also recently added to or reduced their stakes in CRL. Brooklyn Investment Group grew its position in Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC grew its position in Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company's stock valued at $27,000 after acquiring an additional 152 shares during the period. HM Payson & Co. acquired a new position in shares of Charles River Laboratories International during the first quarter worth about $31,000. Bayforest Capital Ltd acquired a new position in shares of Charles River Laboratories International during the second quarter worth about $63,000. Finally, Family Legacy Financial Solutions LLC acquired a new position in shares of Charles River Laboratories International during the second quarter worth about $71,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. William Blair upgraded Charles River Laboratories International from a "market perform" rating to an "outperform" rating in a research note on Monday, October 6th. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Mizuho boosted their price objective on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a "neutral" rating in a research note on Friday, October 17th. Jefferies Financial Group upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $142.00 to $195.00 in a research note on Tuesday, September 9th. Finally, Wall Street Zen cut Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Eight investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average price target of $181.29.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Trading Up 2.2%

NYSE:CRL opened at $191.09 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02. The business's 50-day simple moving average is $163.61 and its 200 day simple moving average is $149.60. The stock has a market cap of $9.40 billion, a price-to-earnings ratio of -143.67, a price-to-earnings-growth ratio of 5.01 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $983.76 million. During the same quarter in the previous year, the firm posted $2.80 earnings per share. The company's revenue was up .6% compared to the same quarter last year. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.